Market Cap ₹6592 Cr.
Stock P/E 40.8
P/B 4
Current Price ₹380
Book Value ₹ 94.6
Face Value 2
52W High ₹433.3
Dividend Yield 0%
52W Low ₹ 319.4
Blue Jet Healthcare Ltd is a dynamic and innovative company in the healthcare sector, dedicated to providing high-quality medical solutions. Specializing in cutting-edge technologies, the company focuses on the development, manufacturing, and distribution of medical devices and pharmaceuticals. With a commitment to improving patient outcomes, Blue Jet Healthcare emphasizes research and development, ensuring its products meet the highest standards of safety and efficacy. The company also places a strong emphasis on sustainability and ethical business practices, contributing to a healthier future for individuals and communities. Blue Jet Healthcare Ltd strives to be a leader in the healthcare industry by combining expertise, innovation, and a passion for enhancing global well-being.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
#(Fig in Cr.) | Sep 2022 | Dec 2022 | Sep 2023 | Dec 2023 |
---|---|---|---|---|
Net Sales | 190 | 169 | 181 | 167 |
Other Income | 7 | 6 | 8 | 7 |
Total Income | 197 | 175 | 190 | 174 |
Total Expenditure | 132 | 117 | 119 | 112 |
Operating Profit | 66 | 58 | 71 | 61 |
Interest | 0 | 0 | 0 | 0 |
Depreciation | 6 | 7 | 6 | 8 |
Exceptional Income / Expenses | 0 | 0 | 0 | -10 |
Profit Before Tax | 59 | 51 | 64 | 44 |
Provision for Tax | 15 | 14 | 16 | 12 |
Profit After Tax | 44 | 38 | 48 | 32 |
Adjustments | -0 | 0 | 0 | 0 |
Profit After Adjustments | 44 | 38 | 48 | 32 |
Adjusted Earnings Per Share | 2.5 | 2.2 | 2.8 | 1.9 |
#(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
---|---|---|---|---|
Net Sales | 499 | 683 | 721 | 707 |
Other Income | 9 | 19 | 24 | 28 |
Total Income | 508 | 703 | 745 | 736 |
Total Expenditure | 292 | 434 | 502 | 480 |
Operating Profit | 215 | 269 | 243 | 256 |
Interest | 5 | 3 | 1 | 0 |
Depreciation | 20 | 22 | 25 | 27 |
Exceptional Income / Expenses | 0 | 0 | 0 | -10 |
Profit Before Tax | 190 | 243 | 217 | 218 |
Provision for Tax | 49 | 62 | 57 | 57 |
Profit After Tax | 142 | 182 | 160 | 162 |
Adjustments | 0 | 0 | -0 | 0 |
Profit After Adjustments | 142 | 182 | 160 | 162 |
Adjusted Earnings Per Share | 8.2 | 10.5 | 9.2 | 9.4 |
# | 1 Year | 3 Year | 5 Year | 10 Year |
---|---|---|---|---|
Sales CAGR | 6% | 0% | 0% | 0% |
Operating Profit CAGR | -10% | 0% | 0% | 0% |
PAT CAGR | -12% | 0% | 0% | 0% |
# | 1 Year | 3 Year | 5 Year | 10 Year |
---|---|---|---|---|
Share Price CAGR | NA% | NA% | NA% | NA% |
ROE Average | 27% | 37% | 37% | 37% |
ROCE Average | 36% | 47% | 47% | 47% |
#(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|
Shareholder's Funds | 340 | 522 | 681 |
Minority's Interest | 0 | 0 | 0 |
Borrowings | 29 | 0 | 0 |
Other Non-Current Liabilities | 5 | 17 | 7 |
Total Current Liabilities | 220 | 259 | 318 |
Total Liabilities | 593 | 798 | 1007 |
Fixed Assets | 139 | 156 | 151 |
Other Non-Current Assets | 7 | 9 | 46 |
Total Current Assets | 447 | 633 | 810 |
Total Assets | 593 | 798 | 1007 |
#(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|
Opening Cash & Cash Equivalents | 10 | 61 | 75 |
Cash Flow from Operating Activities | 135 | 146 | 142 |
Cash Flow from Investing Activities | -56 | -76 | -147 |
Cash Flow from Financing Activities | -27 | -56 | -4 |
Net Cash Inflow / Outflow | 51 | 14 | -10 |
Closing Cash & Cash Equivalent | 61 | 75 | 65 |
# | Mar 2021 | Mar 2022 | Mar 2023 |
---|---|---|---|
Earnings Per Share (Rs) | 8.16 | 10.47 | 9.23 |
CEPS(Rs) | 9.3 | 11.75 | 10.67 |
DPS(Rs) | 0 | 0 | 0 |
Book NAV/Share(Rs) | 19.59 | 30.07 | 39.29 |
Core EBITDA Margin(%) | 41.46 | 36.47 | 30.39 |
EBIT Margin(%) | 39.24 | 36.07 | 30.23 |
Pre Tax Margin(%) | 38.18 | 35.59 | 30.04 |
PAT Margin (%) | 28.38 | 26.57 | 22.2 |
Cash Profit Margin (%) | 32.32 | 29.81 | 25.67 |
ROA(%) | 23.87 | 26.11 | 17.74 |
ROE(%) | 41.67 | 42.16 | 26.6 |
ROCE(%) | 50.03 | 54.01 | 36.24 |
Receivable days | 105.35 | 99.18 | 118.17 |
Inventory Days | 86.12 | 59.48 | 58.39 |
Payable days | 128.23 | 73.7 | 59.93 |
PER(x) | 0 | 0 | 0 |
Price/Book(x) | 0 | 0 | 0 |
Dividend Yield(%) | 0 | 0 | 0 |
EV/Net Sales(x) | -0.02 | -0.08 | -0.04 |
EV/Core EBITDA(x) | -0.04 | -0.2 | -0.13 |
Net Sales Growth(%) | 0 | 36.99 | 5.49 |
EBIT Growth(%) | 0 | 25.91 | -11.58 |
PAT Growth(%) | 0 | 28.23 | -11.88 |
EPS Growth(%) | 0 | 28.22 | -11.88 |
Debt/Equity(x) | 0.15 | 0 | 0 |
Current Ratio(x) | 2.03 | 2.44 | 2.54 |
Quick Ratio(x) | 1.5 | 2.04 | 2.15 |
Interest Cover(x) | 36.89 | 74.71 | 160.39 |
Total Debt/Mcap(x) | 0 | 0 | 0 |
# | Dec 2023 | Mar 2024 |
---|---|---|
Promoter | 86 | 86 |
FII | 2.93 | 2.01 |
DII | 3.7 | 3.03 |
Public | 7.37 | 8.96 |
Others | 0 | 0 |
Total | 100 | 100 |
# | Dec 2023 | Mar 2024 |
---|---|---|
Promoter | 14.92 | 14.92 |
FII | 0.51 | 0.35 |
DII | 0.64 | 0.53 |
Public | 1.28 | 1.55 |
Others | 0 | 0 |
Total | 17.35 | 17.35 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
You May Also Know About